Emergent Biosolutions (EBS) Competitors

Johnson & Johnson (NYSE:JNJ) and Emergent Biosolutions (NYSE:EBS) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk, dividends and media sentiment.

Is JNJ or EBS more profitable?

Johnson & Johnson has a net margin of 24.42% compared to Emergent Biosolutions' net margin of -13.63%. Johnson & Johnson's return on equity of 33.46% beat Emergent Biosolutions' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Johnson & Johnson	24.42%	33.46%	13.30%
Emergent Biosolutions	-13.63%	-0.52%	-0.17%

Do analysts prefer JNJ or EBS?

Johnson & Johnson presently has a consensus price target of $171.00, suggesting a potential upside of 8.42%. Emergent Biosolutions has a consensus price target of $14.33, suggesting a potential upside of 95.54%. Given Emergent Biosolutions' stronger consensus rating and higher probable upside, analysts clearly believe Emergent Biosolutions is more favorable than Johnson & Johnson.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Johnson & Johnson	0 Sell rating(s)	11 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.55
Emergent Biosolutions	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Do insiders and institutionals hold more shares of JNJ or EBS?

69.6% of Johnson & Johnson shares are held by institutional investors. Comparatively, 78.4% of Emergent Biosolutions shares are held by institutional investors. 0.2% of Johnson & Johnson shares are held by company insiders. Comparatively, 1.2% of Emergent Biosolutions shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Which has more risk & volatility, JNJ or EBS?

Johnson & Johnson has a beta of 0.41, indicating that its stock price is 59% less volatile than the S&P 500. Comparatively, Emergent Biosolutions has a beta of 2.09, indicating that its stock price is 109% more volatile than the S&P 500.

Which has better earnings and valuation, JNJ or EBS?

Johnson & Johnson has higher revenue and earnings than Emergent Biosolutions. Emergent Biosolutions is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Johnson & Johnson	$88.82B	4.27	$14.07B	$8.99	17.54
Emergent Biosolutions	$1.04B	0.38	-$190.60M	-$2.71	-2.70

Does the media refer more to JNJ or EBS?

In the previous week, Johnson & Johnson had 108 more articles in the media than Emergent Biosolutions. MarketBeat recorded 114 mentions for Johnson & Johnson and 6 mentions for Emergent Biosolutions. Johnson & Johnson's average media sentiment score of 1.37 beat Emergent Biosolutions' score of 0.78 indicating that Johnson & Johnson is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Johnson & Johnson	97 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Positive
Emergent Biosolutions	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Johnson & Johnson beats Emergent Biosolutions on 12 of the 17 factors compared between the two stocks.